CEFTAROLINE FOSAMIL
CEFTAROLINE FOSAMIL is indicated for the treatment of Acute Bacterial Skin and Skin Structure Infections; Community-Acquired Bacterial Pneumonia.
How CEFTAROLINE FOSAMIL Works
Ceftaroline works as a cephalosporin antibacterial drug. It acts against specific Gram-positive and Gram-negative microorganisms to resolve bacterial infections in the skin and lungs.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2021-09-21
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
CEFTAROLINE FOSAMIL Approval History
What CEFTAROLINE FOSAMIL Treats
2 indicationsCEFTAROLINE FOSAMIL is approved for 2 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Acute Bacterial Skin and Skin Structure Infections
- Community-Acquired Bacterial Pneumonia
CEFTAROLINE FOSAMIL Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CEFTAROLINE FOSAMIL
3 of 8FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT02806882 Ceftaroline | Chavanet AZ 2014 | Ph 1 | completed | Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF) |
| NCT02335905 results posted | H-35130 TEF-IT-43/IIT-2017-10048 | Ph 1, Ph 2 | completed | Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children |
| NCT02424734 results posted | D3720C00009 C2661002, 2014-003243-34 | Ph 2 | terminated | Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis |
| NCT02202135 results posted | D3720C00001sub | Ph 3 | terminated | Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections. |
| NCT01499277 results posted | D3720C00001 2011-004013-16 | Ph 3 | completed | Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections |
| NCT01645735 results posted | P903-25 | Ph 4 | completed | Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus |
| NCT01669980 | P903-24 | Ph 4 | completed | Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP) |
| NCT01400867 | P903-23 | Ph 2, Ph 3 | completed | Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections |
| NCT01530763 | P903-31 | Ph 2, Ph 3 | completed | Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) |
| NCT01701219 | CPT-MD-32 | Ph 4 | completed | Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia |
| NCT01298843 | P903-21 | Ph 4 | completed | Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital |
| NCT01666743 | CPT-MD-34 | Ph 4 | withdrawn | Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFTAROLINE FOSAMIL FDA Label Details
Indications & Usage
CEFTAROLINE FOSAMIL is indicated for the treatment of Acute Bacterial Skin and Skin Structure Infections; Community-Acquired Bacterial Pneumonia.
Looking for the branded version?
TEFLARO
Full clinical data, patents, trials, and competitive landscape for ceftaroline fosamil.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment